Mainstreaming genetics in palliative care: barriers and suggestions for clinical genetic services
- 84 Downloads
Palliative healthcare professionals (PHCPs) frequently do not refer their eligible patients for genetic testing. After the death of the affected individual, clinically relevant information for family members is lost. In previous research, PHCPs stated that the end-of-life setting is not appropriate to discuss genetic issues. It is unclear if this has changed due to increasing awareness of genetics in the media and efforts to mainstream genetic testing. Semi-structured interviews of PHCPs were analysed by thematic analysis. Seven PHCPs (four nurses, two consultants, and one clinical psychologist) were interviewed. Participants reported feeling unfamiliar with the role of clinical genetics services, and did not feel confident in addressing genetic issues with their patients. A lack of scientific knowledge and unawareness of existing infrastructure to support their patients were cited. Many stated that palliative patients are interested in exploring a potential hereditary component to their disease, and acknowledged the potential for psychological benefit for their patients and their families. Most stated that addressing genetics fits within their skill set, but expressed concern about issues of consent, logistical difficulties, and ethical dilemmas. These perceptions differ considerably from those reported in existing literature. Importantly, each participant stated that the potential benefits of addressing genetic issues outweighed the potential for harm in most cases. These results suggest a need for clinical genetics staff to develop closer links with their local PHCPs and to provide education. Clinical psychologists may also be a helpful resource to address PHCPs’ concerns.
No funding was obtained for this study.
Compliance with ethical standards
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Informed consent was obtained from all individual participants included in the study.
Conflict of interest
The authors declare that they have no conflict of interest.
- Cardiff University (2015) Managing your data after your project has completed. Cardiff University Information Services. http://www.cardiff.ac.uk/insrv/researchdata/aftertheproject/index.html (accessed 9 Aug 2015)
- Daniels MS, Burzawa JK, Brandt AC, Schmeler KM, Lu KH (2011) A clinical perspective on genetic counseling and testing during end of life care for women with recurrent progressive ovarian cancer: opportunities and challenges. Familial Cancer 10(2):193–197. https://doi.org/10.1007/s10689-011-9418-1 CrossRefPubMedPubMedCentralGoogle Scholar
- Evans DGR, Barwell J, Eccles DM, Collins A, Izatt L, Jacobs C, Donaldson A, Brady AF, Cuthbert A, Harrison R, Thomas S, Howell A, The FH02 Study Group, RGC teams, Miedzybrodzka Z, Murray A (2012) The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services. Breast Cancer Res 19(5):442Google Scholar
- Kentwell M, Dow E, Antill Y, Wrede CD, McNally O, Higgs E, Hamilton A, Ananda S, Lindeman GJ, Scott CL (2017) Mainstreaming cancer genetics: a model integrating germline BRCA testing into routine ovarian cancer clinics. Gynecol Oncol 145(1):130–136. https://doi.org/10.1016/j.ygyno.2017.01.030 CrossRefPubMedGoogle Scholar
- Kessler S (1997) Psychological aspects of genetic counselling. Am J Med Genet 72(2):164–171. https://doi.org/10.1002/(SICI)1096-8628(19971017)72:2<164::AID-AJMG8>3.0.CO;2-V CrossRefPubMedGoogle Scholar
- Matulonis UA, Wulf GM, Barry WT, Birrer M, Westin SN, Faroog S, Bell-McGuinn KM, Obermayer E, Whalen C, Spagnoletti T, Luo W, Liu H, Hok RC, Aghajanian C, Solit DB, Mills GB, Taylor BS, Won H, Berger MF, Palakurthi S, Liu J, Cantley LC, Winer E (2016) Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high grade serous ovarian and breast cancer. Ann Oncol:mdw672. https://doi.org/10.1093/annonc/mdw672
- NCCN (2016) Clinical practice guidelines in oncology: genetic/familial high risk assessment: breast & ovarian Version 2.2016 ed. www.nccn.org/professionals/physician_gls/pdg/genetics_screening.pdf (accessed on 1 Apr 2017)
- NICE (2010) Familial breast cancer: Classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer. https://www.nice.org.uk/guidance/cg164/ifp/chapter/genetic-counselling-and-genetic-testing (2010, accessed on 13 July 2015)
- Novetsky AP, Smith K, Babb SA, Jeffe DB, Hagemann AR, Thaker PH, Powell MA, Mutch DG, Massad LS, Zighelboim I (2013) Timing of referral for genetic counseling and genetic testing in patients with ovarian, fallopian tube or primary peritoneal carcinoma. Int J Gynecol Cancer 23(6):1016–1021. https://doi.org/10.1097/IGC.0b013e3182994365 CrossRefPubMedGoogle Scholar
- Paluch-Shimon S, Cardoso F, Sessa C, Balmana J, Cardoso MJ, Gilbert F, Senkus E (2016) Prevention and screening in BRCA mutation carriers and other breast/ovarian hereditary cancer syndromes: ESMO clinical practice guidelines for cancer prevention and screening. Ann Oncol 27(5):v103–v110. https://doi.org/10.1093/annonc/mdw327 CrossRefPubMedGoogle Scholar
- Quillin J, Bodurtha J, Siminoff L, Smith T (2010) Exploring hereditary cancer among dying cancer patients—a cross-sectional study of hereditary risk and perceived awareness of DNA testing and banking. J Genet Couns 19(5):497–525. https://doi.org/10.1007/s10897-010-9308-y CrossRefPubMedPubMedCentralGoogle Scholar
- Vadaparampil S, Quinn GP, Dutil J, Puig M, Malo TL, McIntyre J, Perales R, August EM, Closser Z (2011) A pilot study of knowledge and interest of genetic counseling and testing for hereditary breast and ovarian cancer syndrome among Puerto Rican women. J Community Genet. 2(4):211–221. https://doi.org/10.1007/s12687-011-0058-9 CrossRefPubMedPubMedCentralGoogle Scholar
- Weren RD, Mensenkamp AR, Simons M, Eijkelenboom A, As S, Ouchene H, van Asseldonk M, Gomez-Garcia EB, Blok MJ, de Hullu JA, Nelen MR, Hoischen A, Bulten J, Tops BB, Hoogerbrugge N, Ligtenberg MJ (2017) Novel BRCA1 and BRCA2 tumor test as basis for treatment decisions and referral for genetic counselling of patients with ovarian carcinomas. Hum Mutat 38(2):226–235. https://doi.org/10.1002/humu.23137 CrossRefPubMedGoogle Scholar